The role of allogeneic haematopoietic progenitor cell transplantation in patients with diffuse large B-cell non-Hodgkin lymphomas (DLBCL)

Bone Marrow Transplantation

Volumn 48, Issue 10, 2013, Pages 1271-1278

  Papageorgiou, S G ^a,b   Cwynarski, K ^a   Kottaridis, P D ^a  

^a ROYAL FREE HOSPITAL   (United Kingdom)

^b UNIVERSITY OF ATHENS   (Greece)

Author keywords

90Y ibritumomab tiuxetan; allogeneic haematopoietic cell transplantation; diffuse large B cell lymphomas; rituximab

Indexed keywords

ALEMTUZUMAB; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; IBRITUMOMAB TIUXETAN; IMMUNOSUPPRESSIVE AGENT; MELPHALAN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RITUXIMAB; TACROLIMUS; THIOTEPA; TOSITUMOMAB I 131;

ACUTE GRAFT VERSUS HOST DISEASE; ADJUVANT THERAPY; AGE; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; CHEMOSENSITIVITY; CHRONIC GRAFT VERSUS HOST DISEASE; DISEASE COURSE; DISEASE FREE SURVIVAL; DONOR LYMPHOCYTE INFUSION; DRUG DOSE ESCALATION; DRUG WITHDRAWAL; EVENT FREE SURVIVAL; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LYMPHOMA EFFECT; HUMAN; KARNOFSKY PERFORMANCE STATUS; LARGE CELL LYMPHOMA; MANTLE CELL LYMPHOMA; MORTALITY; MYELOABLATIVE CONDITIONING; NONHODGKIN LYMPHOMA; NONMYELOABLATIVE CONDITIONING; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECURRENCE RISK; REDUCED INTENSITY CONDITIONING; REVIEW; SALVAGE THERAPY; T CELL DEPLETION;

COMBINED MODALITY THERAPY; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS;

EID: 84885593459     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2012.266     Document Type: Review

References (52)

1. Flowers CR, Sinha R, Vose JM. Improving outcomes for patients with diffuse large B-cell lymphoma. CA Cancer J Clin 2010; 60: 393-408.
2. Jaffe ES, Harris NL, Stein H, Vardiman JW (eds). World Health Organization Classification of Tumors of Hematopoietic and Lymphoid Tissues. IARC Press: Lyon, France, 2008.
3. Coiffier B, Lepage E, Briere J, Herbecht R, Tilly H, Bouabdallah R et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma. N Engl J Med 2002; 346: 235-242. (Pubitemid 34438862)
4. Pfreundschuh M, Trümper L, Osterborg A, Pettengell R, Trneny M, Imrie K et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large B-cell lymphoma: a randomized controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006; 7: 379-391.
5. Zelenetz AD, Abramson JS, Advani RH, Andreadis CB, Byrd JC, Czuczman MS et al. NCCN clinical practice guidelines in oncology: non-Hodgkin lymphoma. J Natl Compr Canc Netw 2010; 8: 288-334.
6. Philip T, Guglielmi C, Hagenbeek A, Somers R, Van der Lelie H, Bron D et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin lymphoma N Engl J Med 1995; 333: 1540-1545.
7. Ardeshna KM, Kakouros N, Qian W, Powell MG, Saini N, D'Sa S et al. Conventional second-line salvage chemotherapy in patients with malignant lymphomas who have progressive disease after first-line salvage therapy regimens. Br J Haem 2005; 130: 363-372. (Pubitemid 43899584)
8. Vose JM, Zhang MJ, Rowlings PA, Lazarus HM, Bolwell BJ, Freytes CO et al. Autologous transplantation for diffuse aggressive non-Hodgkin's lymphoma in patients never achieving remission: a report from the Autologous Blood and Marrow Transplant Registry. J Clin Oncol 2001; 19: 406-413. (Pubitemid 32112852)
9. Oliansky DM, Czuczman M, Fisher RI, Irwin FD, Lazarus HM, Omel J et al. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of diffuse large B cell lymphoma: update of the 2001 evidence-based review. Biol Blood Marrow Transplant 2011; 17: 20-47e30.
10. Gisselbrecht C, Glass B, Mounier N, Singh Gill D, Linch DC, Trneny M et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol 2010; 28: 4184-4190.
11. Mounier N, Gisselbrecht C. Stem cell transplantation for diffuse large B-cell lymphoma patients in the rituximab era. Curr Opin Oncol 2011; 23: 209-213.
12. Peniket AJ, Ruiz de Elvira MC, Taghipour G, Cordonnier C, Gluckman E, de Witte T et al. An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation. Bone Marrow Transplant 2003; 31: 667-678. (Pubitemid 36553477)
13. van Besien K, Loberiza FR, Bajorunaite R, Armitage JO, Bashey A, Burns LJ et al. Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma. Blood 2003; 102: 3521-3529. (Pubitemid 37409366)
14. Bloor AJ, Thomson K, Chowdhry N, Verfuerth S, Ings SJ, Chakraverty R et al. High response rate to donor lymphocyte infusion after allogeneic stem cell transplantation for indolent non-Hodgkin lymphoma. Biol Blood Marrow Transplant 2008; 14: 50-58. (Pubitemid 350286737)
15. Deol A, Lum L. Role of donor lymphocyte infusions in relapsed haematological malignancies after stem cell transplantation revisited. Cancer Treat Rev 2010; 36: 528-538.
16. Lazarus HM, Zhang MJ, Carreras J, Hayes-Lattin BM, Ataergin AS, Bitran JD et al. A comparison of HLA-identical sibling allogeneic versus autologous transplantation for diffuse large B cell lymphoma: a report from the CIBMTR. Biol Blood Marrow Transplant 2010; 16: 35-45.
17. Aksentijevich I, Jones RJ, Ambinder RF, Garrett-Mayer E, Flinn IW. Clinical outcome following autologous and allogeneic blood and marrow transplantation for relapsed diffuse large-cell non-Hodgkin's lymphoma. Biol Blood Marrow Transplant 2006; 12: 965-972.
18. van Besien KW, de Lima M, Giralt SA, Moore Jr DF, Khouri IF, Rondón G et al. Management of lymphoma recurrence after allogeneic transplantation: the relevance of graft-versus-lymphoma effect. Bone Marrow Transplant 1997; 19: 977-982. (Pubitemid 27232173)
19. Schimmer AD, Jamal S, Messner H, Keating A, Meharchand J, Huebsch L et al. Allogeneic or autologous bone marrow transplantation (BMT) for non-Hodgkin's lymphoma (NHL): results of a provincial strategy. Ontario BMT Network, Canada. Bone Marrow Transplant 2000; 26: 859-864.
20. Ratanatharathorn V, Uberti J, Karanes C, Abella E, Lum LG, Momin F et al. Prospective comparative trial of autologous versus allogeneic bone marrow transplantation in patients with non-Hodgkin's lymphoma. Blood 1994; 84: 1050-1055. (Pubitemid 24245868)
21. Morris E, Thomson K, Craddock C, Mahendra P, Milligan D, Cock G et al. Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma. Blood 2004; 104: 3865-3871. (Pubitemid 39620131)
22. Bishop MR, Dean RM, Steinberg SM, Odom J, Pavletic SZ, Chow C et al. Clinical evidence of a graft-versus-lymphoma effect against relapsed diffuse large B-cell lymphoma after allogeneic hematopoietic stem-cell transplantation. Ann Oncol 2008; 19: 1935-1940.
23. Thomson KJ, Morris EC, Bloor A, Cock G, Milligan D, Parker A et al. Favorable longterm survival after reduced-intensity allogeneic transplantation for multiplerelapse aggressive non-Hodgkin's lymphoma. J Clin Oncol 2009; 27: 426-432.
24. Wudhikarn K, Brunstein CG, Bachanova V, Burns LJ, Cao Q, Weisdorf DJ. Relapse of lymphoma after allogeneic hematopoietic cell transplantation: management strategies and outcome. Biol Blood Marrow Transplant 2011; 10: 1497-1504.
25. Van Besien K, Carreras J, Bierman P, Logan BR, Molina A, King R et al. Unrelated donor hematopoietic cell transplantation for non-Hodgkin Lymphoma: long-term outcomes. Biol Blood Marrow Transplant 2009; 15: 554-563.
26. Doocey R, Toze C, Connors J, Nevill T, Gascoyne R, Barnett M et al. Allogeneic haematopoietic stem-cell transplantation for relapsed and refractory aggressive histology non-Hodgkin lymphoma. Br J Haematol 2005; 131: 223-230. (Pubitemid 43899690)
27. Kim SW, Tanimoto TE, Hirabayashi N, Goto S, Kami M, Yoshioka S et al. Myeloablative allogeneic hematopoietic stem cell transplantation for non-Hodgkin lymphoma: a nationwide survey in Japan. Blood 2006; 108: 382-389. (Pubitemid 43990653)
28. Van Kampen RJW, Canals C, Schouten HC, Nagler A, Thomson KJ, Vernant JP et al. Allogeneic stem-cell tansplantation as salvage therapy for patients with diffuse large B-cell non-Hodgkin lymphoma relapsing after autologous stem-cell transplantation: an analysis of the European Group for Blood and Marrow Transplantation Registry. J Clin Oncol 2011; 29: 1342-1348.
29. Freytes CO, Loberiza FR, Rizzo JD, Bashey A, Bredeson CN, Cairo MS et al. Myeloablative allogeneic hematopoietic stem cell transplantation in patients who experience relapse after autologous stem cell transplantation for lymphoma: a report from the International Bone Marrow Transplant Registry. Blood 2004; 104: 3797-3803. (Pubitemid 39564460)
30. Slavin S, Nagler A, Naparstek E, Kapelushnik Y, Aker M, Cividalli G et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998; 91: 756-763. (Pubitemid 28078275)
31. Nagler A, Slavin S, Varadi G, Naparstek E, Samuel S, Or R. Allogeneic peripheral blood stem cell transplantation using a fludarabine-based low intensity conditioning regimen for malignant lymphoma. Bone Marrow Transpl 2000; 25: 1021-1028. (Pubitemid 30303589)
32. Robinson SP, Goldstone AH, Mackinnon S, Carella A, Russell N, de Elvira CR et al. Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of European Group for Blood and Bone Marrow Transplantation. Blood 2002; 100: 4310-4316. (Pubitemid 35429668)
33. Corradini P, Dodero A, Farina L, Fanin R, Patriarca F, Miceli R et al. Allogeneic stem cell transplantation following reduced-intensity conditioning can induce durable clinical and molecular remissions in relapsed lymphomas: pre-transplant disease status and histotype heavily influence outcome. Leukemia 2007; 21: 2316-2323. (Pubitemid 350011704)
34. Rezvani AR, Norasetthada L, Gooley T, Sorror M, Bouvier ME, Sahebi F et al. Non-myeloablative allogeneic haematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: a multicentre experience. Br J Haematol 2008; 143: 395-403.
35. Sirvent A, Dhedin N, Michallet M, Mounier N, Faucher C, Yakoub-Agha I et al. Low norelapse mortality and prolonged long-term survival after reduced-intensity allogeneic stem cell transplantation for relapsed or refractory diffuse large B-cell lymphoma: report of the Socié té Francaise de Greffe de Moelle et de Thérapie Cellulaire. Biol Blood Marrow Transplant 2010; 16: 78-85.
36. Warlick ED, Tomblyn M, Cao Q, Defor T, Blazar BR, Macmillan M et al. Reduced-intensity conditioning followed by related allografts in hematologic malignancies: long-term outcomes most successful in indolent and aggressive non-Hodgkin lymphomas. Biol Blood Marrow Transplant 2011; 17: 1025-1032.
37. Rodriguez R, Nademanee A, Ruel N, Smith E, Krishnan A, Popplewell L et al. Comparison of reduced-intensity and conventional myeloablative regimens for allogeneic transplantation in non-Hodgkin's lymphoma. Biol Blood Marrow Transplant 2006; 12: 1326-1334. (Pubitemid 44858267)
38. Rodrigues CA, Patah PA, Novis Y, Hosing C, de Lima M. The role of transplantation in diffuse large B-cell lymphoma: the impact of Rituximab plus chemotherapy in first-line and relapsed settings. Curr Hematol Malig Rep 2011; 6: 47-57.
39. Ratanatharathorn V, Logan B, Wang D, Horowitz M, Uberti JP, Ringden O et al. Prior rituximab correlates with less acute graft-versus-host-disease and better survival in B-cell lymphoma patients who received allogeneic peripheral blood stem cell transplantation. Br J Haematol 2009; 145: 816-824.
40. Khouri IF, McLaughlin P, Saliba RM, Hosing C, Korbling M, Lee MS et al. Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab. Blood 2008; 111: 5530-5536.
41. Schultz KR, Paquet J, Bader S, HayGlass KT. Requirement for B cells in T cell priming to minor histocompatibility antigens and development of graftversus-host disease. Bone Marrow Transplant 1995; 16: 289-295.
42. Iori AP, Torelli GF, De Propris MS, Milano F, Pupella S, Gozzer M et al. B-cell concentration in the apheretic product predicts acute graft-versus-host disease and treatment-related mortality of allogeneic peripheral blood stem cell transplantation. Transplantation 2008; 85: 386-390. (Pubitemid 351322762)
43. Mohty M, Marchetti N, El-Cheikh J, Faucher C, Furst S, Blaise D. Rituximab as salvage therapy for refractory chronic GVHD. Bone Marrow Transplant 2008; 41: 909-911. (Pubitemid 351761695)
44. Cutler C, Miklos D, Kim HT, Treister N, Woo SB, Bienfang D et al. Rituximab for steroid-refractory chronic graft-versus-host disease. Blood 2006; 108: 756-762. (Pubitemid 44061381)
45. Gisselbrect C, Vose J, Nademanee A, Gianni AM, Nagler A. Radioimmunotherapy for stem cell transplantation in non-Hodgkin's lymphoma: in pursuit of a complete response. Oncologist 2009; 14: 41-51.
46. Winter JN, Inwards DJ, Spies S, Wiseman G, Patton D, Erwin W et al. Yttrium-90 ibritumomab tiuxetan doses calculated to deliver up to 15Gy to critical organs may be safely combined with high-dose BEAM and autologous transplantation in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol 2009; 27: 1653-1659.
47. Gopal AK, Rajendran JC, Gooley TA, Pagel JM, Fisher DR, Petersdorf SH et al. High-dose [131] tositumomab (anti-CD20) radioimmunotherapy and autologous hematopoietic stem-cell transplantation for adults4or60 years old with relapsed or refractory B-cell lymphomas. J Clin Oncol 2007; 25: 1396-1402. (Pubitemid 46706888)
48. Gopal AK, Guthrie KA, Rajendran J, Pagel JM, Oliveira G, Maloney DG et al. 90Y-ibritumomab tiuxetan, fludarabine and TBI based non-myeloablative allogeneic transplant conditioning for patients with persistent high-risk B-cell lymphoma. Blood 2011; 118: 1132-1139.
49. Bethge WA, von Harsdorf S, Bornhauser M, Federmann B, Stelljes M, Trenschel R et al. Dose-escalated radioimmunotherapy as part of reduced intensity conditioning for allogeneic transplantation in patients with advanced high-grade non-Hodgkin lymphoma. Bone Marrow Transplant 2012; 47: 1397-1402.
50. Cuccuini W, Briere J, Mounier N, Voelker HU, Rosenwald A, Sundstrom C et al. MYC diffuse large B-cell lymphoma is not salvaged by classical R-ICE or R-DHAP followed by BEAM plus autologous stem cell transplantation. Blood 2012; 119: 4619-4624.
51. Thieblemont C, Briere J, Mounier N, Voelker HU, Cuccuini W, Hirchaud E et al. The germinal center/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed/refractory diffuse large B-cell lymphoma: a bio-CORAL study. J Clin Oncol 2011; 29: 4079-4087.
52. Foon KA, Takeshita K, Zinzani PL. Novel therapies for aggressive B-cell lymphoma. Adv Hematol 2012; 2012: 1-22.